[{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"SymBio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Liquid","sponsorNew":"SymBio Pharmaceuticals \/ SymBio Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"SymBio Pharmaceuticals \/ SymBio Pharmaceuticals"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brincidofovir","moa":"DNA polymerase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"SyB C-0501","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SyB C-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"SyB C-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"SyB C-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"SyB C-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SyB D-0701","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Patch","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SyB L-0501RI","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SyB L-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SyB L-1101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SyB P-1501","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SymBio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SyB V-1901","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"SymBio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SymBio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SymBio Pharmaceuticals \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by SymBio Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
